Description
Prashanthan Sanders, MBBS, PhD, FHRS of the University of Adelaide as he discusses Magnetic resonance imaging based Dual lead cardiac Resynchronization therapy: A prospective Left Bundle Branch Pacing Study (MADURAI LBBP study) by Heart Rhythm 2023 Late-Breaking Abstract Author Shunmuga Sundaram Ponnusamy. He is joined by guests Rakesh Gopinathannair, MA, MD, FHRS of the Kansas City Heart Rhythm Institute and Martin K. Stiles, MBChB, PhD, FHRS of Waikato Hospital, Cardiology. This episode of The Lead was recorded in front of live audience at Heart Rhythm 2023 in New Orleans, Lousiana.
Learning Objectives
- Analyze the left bundle branch pacing study.
Article Authors and Podcast Contributors
Article Authors
Shunmuga Sundaram Ponnusamy, MBBS, MD, CEPS-A; Vidhya Ganesan, MD; Vadivelu Ramalingam, MD; Thabish Syed, MD; Selvaganesh Mariappan, MD; Senthil Murugan, MD; Mahesh Kumar, MD; Vijesh Anand, MD; Mariappan Murugan, MD; Pugazhendhi Vijayaraman, MD, FHRS
Podcast Contributors
Rakesh Gopinathannair, MA, MD, FHRS of the Kansas City Heart Rhythm Institute
Prashanthan Sanders, MBBS, PhD, FHRS of the University of Adelaide
Martin K. Stiles, MBChB, PhD, FHRS of Waikato Hospital, Cardiology
Disclosure Policy
All relevant financial relationships have been mitigated.
Host Disclosure(s):
P. Sanders: Honraria/Speaking/Consulting Fee: Abbott, Boston Scientific, Medtronic; Research (Contracted Grants for PIs Named Investigators Only): Abbott, Becton Dickinson, Boston Scientific, CathRx, EBR Systems, Medtronic, Microport Scientific Corporation, PaceMate
Contributor Disclosure(s):
R. Gopinathannair: Honoraria/Speaking/Consulting Fee: Abbott, Boston Scientific, Biosense Webster
M. Stiles: Honoraria/Speaking/Consulting Fee: Medtronic, Cyrix Medical, Pfizer, Sanofi
Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):
J. Glenn: No relevant financial relationships with ineligible companies to disclose.
S. Sailor: No relevant financial relationships with ineligible companies to disclose.